Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Base de datos
País/Región como asunto
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Laryngorhinootologie ; 103(7): 514-521, 2024 Jul.
Artículo en Alemán | MEDLINE | ID: mdl-38387482

RESUMEN

OBJECTIVE: The prevalence of long-/post-COVID-associated chemosensory symptoms is reported in the literature to be significantly higher than clinical reality reflects. METHODS: 1. N= 4062 adults acutely infected with SARS-CoV-2 and their symptoms transmitted by the Jena health office to the Robert Koch Institute between March 2020 and September 2021 were evaluated. 2. Part of the same cohort (N = 909 of 4062) answered an extensive questionnaire at least 3 months after the start of the infection, including existing chemosensory post-COVID-associated complaints. 3. Fourteen post-COVID Jena patients with chemosensory symptoms who had become acutely infected during the same period were diagnosed, treated and advised in our ENT specialist outpatient clinic. RESULTS: The prevalence of chemosensory symptoms at the onset of infection was 19% (600/3187). About every second written respondent of the formerly acutely infected (441/890) remembered chemosensory symptoms during their COVID-19 infection. Of these, around 38% (167/441) complained of persistent chemosensory post-COVID symptoms after an average of 14.5 months. Only 2.3% (14/600) of the previously acutely infected patients with chemosensory symptoms sought medical help in a special consultation. Quantitative chemosensory damage could only be objectified in half, i.e. 1.2% (7/600) of the total cohort. CONCLUSIONS: Despite a high prevalence of subjective chemosensory symptoms in acutely and formerly SARS-CoV-2 infected people, there is only a low need for specialized treatment, so that, unlike other post-COVID-associated complaints, the healthcare system as a whole appears to be less significantly burdened.


Asunto(s)
COVID-19 , SARS-CoV-2 , Humanos , COVID-19/epidemiología , COVID-19/complicaciones , Femenino , Masculino , Adulto , Persona de Mediana Edad , Anciano , Trastornos del Olfato/epidemiología , Trastornos del Olfato/etiología , Trastornos del Olfato/diagnóstico , Alemania , Prevalencia , Encuestas y Cuestionarios , Síndrome Post Agudo de COVID-19 , Estudios de Cohortes
2.
Laryngorhinootologie ; 102(12): 933-943, 2023 12.
Artículo en Alemán | MEDLINE | ID: mdl-37339661

RESUMEN

INTRODUCTION: Olfactory disorders are among the four most common post-COVID-19 complaints. The aim of our prospective study from a university ENT post-COVID consultation (PCS) was to substantiate the symptoms with psychophysical test results. METHODS: After an ENT examination, 60 post-COVID-19 patients (41 women) were asked in writing about their medical history. Their ability to smell was tested using the extended Sniffin' Sticks test battery and their ability to taste was determined using the 3-drop test. From these data, three quantitative olfactory (RD) and gustatory (SD) diagnoses could be defined from normal value tables. Every second patient took part in a control examination. RESULTS: Up to the first examination, 60 patients reported smell and 51 taste disorders; their average duration was 11 months in both cases. Objectified pathologic RD and SD had 87% and 42% of the total cohort, respectively. Every third patient suffered from an objectified combination of olfactory and gustatory damage. About every second patient complained of parosmia. Parosmic patients with two visits came earlier for a check-up. Six months after the initial examination, the detection thresholds, the TDI and the RD had improved in these patients. The self-assessment of olfactory ability had not changed. CONCLUSIONS: Objectified pathologic RD persisted in our PCS for a mean of 1.5 years from the onset of infection. Parosmics had a better prognosis. For the healthcare system and especially for the patients affected, they continue to be a burden even after the pandemic.


Asunto(s)
COVID-19 , Trastornos del Olfato , Humanos , Femenino , Olfato , Estudios Prospectivos , Trastornos del Gusto/diagnóstico , Trastornos del Gusto/etiología , Trastornos del Olfato/diagnóstico , Trastornos del Olfato/etiología
3.
Laryngorhinootologie ; 102(3): 194-202, 2023 03.
Artículo en Alemán | MEDLINE | ID: mdl-36482164

RESUMEN

INTRODUCTION: Disorders of the sense of smell and taste are often complained as a long-COVID symptom. In a special long-COVID consultation (ENT-LCS), we wanted to figure out how large the proportion of pathological olfactory or gustatory diagnoses actually is in this cohort. METHODS: 48 adult patients who visited the ENT-LCS because of their own suffering were asked about their history, rated their ability to smell (SER) and taste (SES) with school grades and completed the extended Sniffin' Sticks test and the 3-drop test as a taste test. Diagnoses were made from the SDI smell score and the total taste score using normative values. Correlations were calculated between the measured scores and the self-assessment and between SER and SES. RESULTS: Pathological chemosensory diagnoses were present in 90%. Pathological olfactory diagnoses were twice as common as gustatory ones. No pathological diagnosis could be verified in 10% of the cohort. Anosmia-ageusia syndrome was diagnosed in six patients. SER correlated strongly with SDI. SES correlated moderately with SScore-total. SER correlated strongly with SES. CONCLUSIONS: There is a risk of smell-taste confusion when interpreting reported chemosensory symptoms. This is another reason why reference is made to the importance of quantifying the chemical senses with validated tests.


Asunto(s)
COVID-19 , Trastornos del Olfato , Adulto , Humanos , Olfato , Gusto , Trastornos del Olfato/diagnóstico , Síndrome Post Agudo de COVID-19 , COVID-19/complicaciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA